Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes
This is a prospective, multi-center imaging study expecting to enroll approximately 2000 patients scheduled for clinically-indicated coronary angiography. Following informed consent, patient will undergo baseline coronary intravascular ultrasound (IVUS) imaging and non-invasive ultrasound imaging of their carotid arteries. Following a 2-year follow-up period, patients will undergo repeat coronary IVUS and standard invasive coronary angiography as well as carotid ultrasound examination.
Additionally, patients will be contacted by phone on an annual basis for 5 years to collect cardiovascular and cerebrovascular clinical endpoints. Evaluations of plaque burden will be made using invasive and non invasive imaging tools in order to assess correlations between vascular beds, imaging technologies and main cardiovascular events.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes|
|Study Start Date:||January 2010|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||September 2014 (Final data collection date for primary outcome measure)|
CTA and PET Substudy:
A subset of patients enrolled into the main CAIN3 study will undergo a CTA. At sites where both CTA and PET imaging modalities exist, patients will be asked to undergo both tests. The CTA and PET scans can be done separately on 2 imaging beds on different days or performed on the same imaging bed, resulting in a combined CTA and PET scan being done in one scheduled visit. All imaging will be done within 90 days after the follow up IVUS.
The choice of radiotracer used (NaF or FDG) for PET imaging will be dependent upon site and availability on the day of the scan. A total of 120 patients will be enrolled in this substudy with approximately 50-60 undergoing CTA and PET.
|Contact: Angel Khaznadjian, M.Sc.||514-461-1300 ext email@example.com|
Show 40 Study Locations
|Study Chair:||Jean-Claude Tardif, MD||Montreal Heart Institute|